The new immunosuppressive agent FK778 attenuates neointima formation in an experimental venous bypass graft model

Vascular Pharmacology

Volumn 50, Issue 3-4, 2009, Pages 83-88

  de Graaf, Rick ^a   Kloppenburg, Geoffrey ^a   Tintu, Andrei ^a   Rouwet, Ellen ^b   Kitslaar, Peter ^a   van Hooff, Johannes ^a   Bruggeman, Cathrien ^a   Stassen, Frank ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

Author keywords

Bypass failure; FK778; Intimal hyperplasia; Neointima; Vein graft

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; IMMUNOSUPPRESSIVE AGENT; KI 67 ANTIGEN; URIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; ARTICLE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EPIGASTRIC ARTERY; FEMORAL ARTERY; GRAFT FAILURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEWIS RAT; MALE; NONHUMAN; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; RAT; SMOOTH MUSCLE FIBER; VEIN BYPASS;

ALKYNES; ANIMALS; BLOOD VESSEL PROSTHESIS; CELL PROLIFERATION; GRAFT OCCLUSION, VASCULAR; IMMUNOSUPPRESSIVE AGENTS; IMPLANTS, EXPERIMENTAL; ISOXAZOLES; MALE; MODELS, ANIMAL; MYOCYTES, SMOOTH MUSCLE; NITRILES; RATS; RATS, INBRED LEW; TUNICA INTIMA; VEINS;

EID: 58549099261     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2008.10.005     Document Type: Article

References (29)

1. Bartlett R.R., Dimitrijevic M., Mattar T., Zielinski T., Germann T., Rude E., Thoenes G.H., Kuchle C.C., Schorlemmer H.U., Bremer E., et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 32 (1991) 10-21
2. Campeau L., Hunninghake D.B., Knatterud G.L., White C.W., Domanski M., Forman S.A., Forrester J.S., Geller N.L., Gobel F.L., Herd J.A., Hoogwerf B.J., and Rosenberg Y. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation 99 (1999) 3241-3247
3. Cherwinski H.M., McCarley D., Schatzman R., Devens B., and Ransom J.T. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J. Pharmacol. Exp. Ther. 272 (1995) 460-468
4. Chesebro J.H., Clements I.P., Fuster V., Elveback L.R., Smith H.C., Bardsley W.T., Frye R.L., Holmes Jr. D.R., Vlietstra R.E., Pluth J.R., Wallace R.B., Puga F.J., Orszulak T.A., Piehler J.M., Schaff H.V., and Danielson G.K. A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N. Engl. J. Med. 307 (1982) 73-78
5. Conte M.S., Mann M.J., Simosa H.F., Rhynhart K.K., and Mulligan R.C. Genetic interventions for vein bypass graft disease: a review. J. Vasc. Surg. 36 (2002) 1040-1052
6. Crews G.M., Erickson L., Pan F., Fisniku O., Jang M.S., Wynn C., Benediktsson H., Kobayashi M., and Jiang H. Down-regulation of TGF-beta and VCAM-1 is associated with successful treatment of chronic rejection in rats. Transplant. Proc. 37 (2005) 1926-1928
7. Czech J., Kurrle R., and Schorlemmer H.U. The antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells is antagonized by exogenous uridine. Inflamm. Res. 48 Suppl 2 (1999) S128-129
8. Deuse T., Hoyt G., Koyanagi T., Robbins R.C., and Schrepfer S. Prevention and inhibition but not reversion of chronic allograft vasculopathy by FK778. Transplantation 85 (2008) 870-877
9. Deuse T., Schrepfer S., Schafer H., Koch-Nolte F., Schwedhelm E., Boger R.H., and Reichenspurner H. FK778 attenuates lymphocyte-endothelium interaction after cardiac transplantation: in vivo and in vitro studies. Transplantation 78 (2004) 71-77
10. Evers D.L., Wang X., Huong S.M., Andreoni K.A., and Huang E.S. Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778. Antiviral. Res. 65 (2005) 1-12
11. Farb A., John M., Acampado E., Kolodgie F.D., Prescott M.F., and Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation 106 (2002) 2379-2384
12. Ge L., Iakovou I., Sangiorgi G.M., Chieffo A., Melzi G., Cosgrave J., Montorfano M., Michev I., Airoldi F., Carlino M., Corvaja N., and Colombo A. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J. Am. Coll. Cardiol. 45 (2005) 989-994
13. Guarda E., Marchant E., Fajuri A., Martinez A., Moran S., Mendez M., Uriarte P., Valenzuela E., and Lazen R. Oral rapamycin to prevent human coronary stent restenosis: a pilot study. Am. Heart. J. 148 (2004) e9
14. Hausleiter J., Kastrati A., Mehilli J., Vogeser M., Zohlnhofer D., Schuhlen H., Goos C., Pache J., Dotzer F., Pogatsa-Murray G., Dirschinger J., Heemann U., and Schomig A. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 110 (2004) 790-795
15. Hoch J.R., Stark V.K., Hullett D.A., and Turnipseed W.D. Vein graft intimal hyperplasia: leukocytes and cytokine gene expression. Surgery 116 (1994) 463-470 discussion 470-461
16. Jahnke T., Schafer F.K., Bolte H., Rector L., Schafer P.J., Brossmann J., Fandrich F., Hedderich J., Heller M., and Muller-Hulsbeck S. 2005 Dr. Gary J. Becker Young Investigator Award: periprocedural oral administration of the leflunomide analogue FK778 inhibits neointima formation in a double-injury rat model of restenosis. J. Vasc. Interv. Radiol. 16 (2005) 903-910
17. Kahan B.D., Van Buren C.T., Weinman E.J., Sandler C.M., Maddox A.M., and Van Horn G. Management of end-stage renal disease by transplantation: the use and limitations of cyclosporine. Tex. Med. 81 (1985) 32-43
18. Linke S.P., Clarkin K.C., Di Leonardo A., Tsou A., and Wahl G.M. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10 (1996) 934-947
19. Mangold U., Dax C.I., Saar K., Schwab W., Kirschbaum B., and Mullner S. Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur. J. Biochem. 266 (1999) 1184-1191
20. Nair R.V., Cao W., and Morris R.E. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Immunol. Lett. 47 (1995) 171-174
21. O'Donohoe M.K., Schwartz L.B., Radic Z.S., Mikat E.M., McCann R.L., and Hagen P.O. Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts. Ann. Surg. 214 (1991) 727-732
22. Porter K.E., Thompson M.M., Loftus I.M., McDermott E., Jones L., Crowther M., Bell P.R., and London N.J. Production and inhibition of the gelatinolytic matrix metalloproteinases in a human model of vein graft stenosis. Eur. J. Vasc. Endovasc. Surg. 17 (1999) 404-412
23. Savikko J., Von Willebrand E., and Hayry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. Transplantation 76 (2003) 455-458 discussion 471-453
24. Schrepfer S., Deuse T., Sultan K.R., Haddad M., Boger R., Munzel T., Schafer H., Pelletier M.P., Robbins R.C., and Reichenspurner H. Inhibition of restenosis development after mechanical injury: a new field of application for malononitrilamides?. Cardiology 108 (2007) 128-137
25. Tangelder M.J., Lawson J.A., Algra A., and Eikelboom B.C. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J. Vasc. Surg. 30 (1999) 701-709
26. Uchimura N., Perera G.B., Fujitani R.M., Tobis J.M., Ishimaru S., Wilson S.E., and Gordon I.L. Dose-dependent inhibition of myointimal hyperplasia by orally administered rapamycin. Ann. Vasc. Surg. 18 (2004) 172-177
27. Vanrenterghem Y., van Hooff J.P., Klinger M., Wlodarczyk Z., Squifflet J.P., Mourad G., Neuhaus P., Jurewicz A., Rostaing L., Charpentier B., Paczek L., Kreis H., Chang R., Paul L.C., Grinyo J.M., and Short C. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation 78 (2004) 9-14
28. Windecker S., Remondino A., Eberli F.R., Juni P., Raber L., Wenaweser P., Togni M., Billinger M., Tuller D., Seiler C., Roffi M., Corti R., Sutsch G., Maier W., Luscher T., Hess O.M., Egger M., and Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N. Engl. J. Med. 353 (2005) 653-662
29. Zeng H., Waldman W.J., Yin D.P., Knight D.A., Shen J., Ma L., Meister G.T., Chong A.S., and Williams J.W. Mechanistic study of malononitrileamide FK778 in cardiac transplantation and CMV infection in rats. Transplantation 79 (2005) 17-22